5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents
Authors:
- 1 December 2013
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 6 (12) , 1263-1266
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)The American Journal of Cardiology, 2011
- Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery DiseaseNew England Journal of Medicine, 2010
- Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trialThe Lancet, 2010
- Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting StentsCirculation, 2009
- Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery DiseaseJAMA, 2008